U. Bosse

710 total citations
27 papers, 545 citations indexed

About

U. Bosse is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, U. Bosse has authored 27 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in U. Bosse's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (7 papers) and HER2/EGFR in Cancer Research (4 papers). U. Bosse is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Diagnosis and Treatment (7 papers) and HER2/EGFR in Cancer Research (4 papers). U. Bosse collaborates with scholars based in Germany, Curacao and Poland. U. Bosse's co-authors include F. Klinke, Michael Thomas, Klaus Junker, U Vogt, C. M. Schlotter, K. Langner, Karsten Schulmann, K.-M. M�ller, Krzysztof Piotr Bielawski and Bogdan Falkiewicz and has published in prestigious journals such as Journal of Clinical Oncology, CHEST Journal and Gene.

In The Last Decade

U. Bosse

26 papers receiving 532 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
U. Bosse Germany 9 297 295 174 103 90 27 545
Robert Weaver United States 5 381 1.3× 295 1.0× 83 0.5× 88 0.9× 62 0.7× 8 545
Iris Nagelmeier Germany 8 366 1.2× 525 1.8× 224 1.3× 133 1.3× 83 0.9× 12 650
Ryan D. Stephenson United States 9 370 1.2× 281 1.0× 185 1.1× 103 1.0× 52 0.6× 18 539
Gabriela Altorjai Austria 12 222 0.7× 366 1.2× 164 0.9× 51 0.5× 59 0.7× 22 545
Minghuan Li China 14 275 0.9× 264 0.9× 249 1.4× 104 1.0× 137 1.5× 32 614
Masatoshi Mukai Japan 9 360 1.2× 170 0.6× 74 0.4× 248 2.4× 100 1.1× 26 604
Shigekazu Ohoyama Japan 10 330 1.1× 398 1.3× 190 1.1× 203 2.0× 172 1.9× 13 654
Kristie Lawhorn United States 6 175 0.6× 294 1.0× 49 0.3× 147 1.4× 72 0.8× 11 459
Renben Wang China 13 249 0.8× 256 0.9× 124 0.7× 99 1.0× 129 1.4× 28 567
Jimmy Pramana Netherlands 5 145 0.5× 178 0.6× 98 0.6× 178 1.7× 46 0.5× 7 458

Countries citing papers authored by U. Bosse

Since Specialization
Citations

This map shows the geographic impact of U. Bosse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Bosse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Bosse more than expected).

Fields of papers citing papers by U. Bosse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Bosse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Bosse. The network helps show where U. Bosse may publish in the future.

Co-authorship network of co-authors of U. Bosse

This figure shows the co-authorship network connecting the top 25 collaborators of U. Bosse. A scholar is included among the top collaborators of U. Bosse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Bosse. U. Bosse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marra, Alessandro, Dirk Kemming, U. Bosse, et al.. (2013). ERCC1 as a predictor of response to induction therapy for stage III non-small cell lung cancer.. Journal of Clinical Oncology. 31(15_suppl). e18511–e18511. 1 indexed citations
2.
Vogt, U, Dirk Kemming, Burkhard Brandt, et al.. (2007). Semi-quantitative gene expression profiling for therapy prediction in a breast cancer neoadjuvant therapy study applying docetaxel/epirubicin/cyclophosphamide. Journal of Clinical Oncology. 25(18_suppl). 21144–21144.
3.
Bosse, U., et al.. (2005). Intravaskuläres Lymphom unter dem klinischen Bild einer therapieresistenten Thrombophlebitis. Phlebologie. 34(3). 171–175. 1 indexed citations
4.
Junker, Klaus, et al.. (2004). Zellul�re Ver�nderungen nicht-kleinzelliger Lungenkarzinome nach neoadjuvanter Therapie. Der Pathologe. 25(3). 193–201. 5 indexed citations
5.
Granetzny, A, U. Bosse, W. Wagner, et al.. (2003). A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer. The Annals of Thoracic Surgery. 75(4). 1107–1112. 6 indexed citations
6.
Schlotter, C. M., et al.. (2003). C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Research. 5(2). R30–6. 59 indexed citations
7.
Junker, Klaus, K.-M. Müller, U. Bosse, et al.. (2003). Apoptose und Tumorregression bei neoadjuvant behandelten lokal fortgeschrittenen nichtkleinzelligen Lungenkarzinomen. Der Pathologe. 24(3). 214–219. 5 indexed citations
8.
Langner, K., Mathew Thomas, F. Klinke, et al.. (2003). Neoadjuvante Therapie des nichtkleinzelligen Lungenkarzinoms. Der Chirurg. 74(1). 42–49. 7 indexed citations
9.
Junker, Klaus, K. Langner, F. Klinke, U. Bosse, & Michael Thomas. (2001). Grading of Tumor Regression in Non-small Cell Lung Cancer. CHEST Journal. 120(5). 1584–1591. 130 indexed citations
10.
Jakob, Christiane, C. M. Schlotter, U. Bosse, & L. Füzesi. (2000). Human Papillomavirus Genotypes in Cervical Cancer with Different Histological Features. Gynecologic and Obstetric Investigation. 50(3). 214–216. 1 indexed citations
11.
Vogt, U, Bogdan Falkiewicz, Krzysztof Piotr Bielawski, U. Bosse, & C. M. Schlotter. (2000). Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.. Acta Biochimica Polonica. 47(1). 157–164. 7 indexed citations
12.
Bosse, U., et al.. (1999). Multicentric Metachronous Central Carcinoid of the Lung: a Case Report. The Thoracic and Cardiovascular Surgeon. 47(5). 337–339. 4 indexed citations
13.
14.
Wagner, W., et al.. (1998). Analysis of long-term survival in patients with locally advanced non-small cell lung cancer.. Oncology Reports. 5(6). 1547–50. 3 indexed citations
15.
Junker, Klaus, Michael Thomas, Karsten Schulmann, et al.. (1997). Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. Journal of Cancer Research and Clinical Oncology. 123(9). 469–477. 134 indexed citations
16.
Junker, Klaus, et al.. (1997). Regressionsgrading neoadjuvant behandelter nichtkleinzelliger Lungenkarzinome. Der Pathologe. 18(2). 131–140. 13 indexed citations
17.
Brandt, Burkhard, U Vogt, Frederike L. Harms, et al.. (1995). Double-differential PCR for gene dosage estimation of erbB oncogenes in benign and cancer tissues and comparison to cellular DNA content. Gene. 159(1). 29–34. 26 indexed citations
18.
19.
Saeger, Wolfgang, et al.. (1995). Prolaktinbildendes Hypophysenkarzinom Kasuistik eines �u�erst seltenen metastasierenden Tumors*. Der Pathologe. 16(5). 354–358. 12 indexed citations
20.
Klinke, F., U. Bosse, & Heinz Höfler. (1990). [The tumorlet carcinoid in bronchiectasis-changed lungs. An example of a multifocal, endocrine tumor].. PubMed. 44 Suppl 1. 607–9. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Weaver Breakdown of academic impact, for papers by Iris Nagelmeier Breakdown of academic impact, for papers by Ryan D. Stephenson Breakdown of academic impact, for papers by Gabriela Altorjai Breakdown of academic impact, for papers by Minghuan Li Breakdown of academic impact, for papers by Masatoshi Mukai Breakdown of academic impact, for papers by Shigekazu Ohoyama Breakdown of academic impact, for papers by Kristie Lawhorn Breakdown of academic impact, for papers by Renben Wang Breakdown of academic impact, for papers by Jimmy Pramana
Rankless by CCL
2026